Los Altos, CA, Boreal Genomics, a developer of sequence-based enrichment

technology, introduced the OnTarget™ Allele Enrichment System today through an early access

program. The OnTarget™ System utilizes Boreal’s novel technology for the depletion of wild-type

alleles with single nucleotide selectivity for improved detection of both known and unknown rare

cancer mutations.

OnTarget™ enables clinicians and oncology researchers to enrich rare cancer mutations at

frequencies down to 0.01% from plasma, frozen or FFPE tissues in less than 2 hours. Early acc ess to

this transformative technology will enable customers to develop highly sensitive oncology assays

to guide clinical decisions during targeted therapy regimens. Furthermore, accurate and sensitive

monitoring will promote early therapeutic decisions when treatment should be altered due to

emergence of drug resistance.

“This is a significant milestone for Boreal Genomics and we are very excited to contribute to efforts

aimed at improving monitoring and early detection of cancer”, said Nitin Sood, Chief Executive

Officer at Boreal Genomics.

In preparation for a wider release of the OnTarget™ System, Boreal will be working alongside

researchers at Stanford University to evaluate improvements to the detection of cancer mutations

in heterogeneous tumor tissue where the majority of isolated DNA does not originate from the

tumor.

Boreal is currently accepting pre-orders for the OnTarget™ System with units planned for shipment

in mid-2012. This week’s AGBT conference will feature a presentation by Dr. Andre Marziali titled

“Multiplexed Enrichment of Rare Alleles” which will discuss the technology and applications of the

OnTarget™ Platform.

For more information please visit https://www.borealgenomics.com

About Boreal Genomics

At Boreal Genomics, we are delivering innovative technologies that enable genetic analysis of the

most challenging samples in life science research and clinical diagnostics. Our methods

revolutionize approaches to total nucleic acid extraction and the targeted enrichment of specific

DNA sequences.

Nucleic acid extraction is commercially available in the Aurora Purification System which enables

recovery of high yield and purity of nucleic acids for successful PCR analysis or sequencing of challenging samples such as soil and environmental matrices rich in inhibitors including oil sands,

sediments and contaminated water; stool; plant tissues and seeds; and difficult forensic casework

specimens. The technology also enables recovery of very high molecular weight DNA from 50 kb –

1 Mb for cloning, library generation, and other genome analysis technologies.

OnTarget™ allele enrichment is a second-generation technology that is capable of unprecedented

enrichment of nucleic acids based on sequence and allows researchers to detect and sequence

both known and unknown rare somatic mutations by performing selective wild-type allele

depletion. By improving the sensitivity of downstream detection assays, OnTarget™ is being

developed to enable non-invasive monitoring of cancer and improved effectiveness of targeted

therapies.

Boreal holds an exclusive license to a broad patent portfolio from the University of British

Columbia on the novel Synchronous Coefficient of Drag Alteration (SCODA) technology.